Section of Vascular Surgery, Department of Surgery, University of Michigan Health System, Ann Arbor, MI, USA.
J Vasc Surg. 2011 Jan;53(1):139-46. doi: 10.1016/j.jvs.2010.07.043. Epub 2010 Sep 24.
Postthrombotic syndrome is characterized by a fibrotic vein injury following deep vein thrombosis (DVT). We sought to quantify the change in vein wall thickness in patients who fail to resolve DVT by 6 months and whether there were differences in blood or plasma levels of inflammatory proteins associated with venous remodeling.
Patients presenting with confirmed lower extremity DVT were prospectively recruited for this study. Duplex imaging of the lower extremity venous system was performed, and blood was collected at entrance and repeat evaluation with blood draw and ultrasound imaging at 1 and 6 months. DVT resolution and thickness of the vein wall was quantified by ultrasound imaging in each segment affected by thrombus, and a contralateral, unaffected vein wall served as a control. Gene and protein expression of inflammatory markers were examined from leukocytes and serum, respectively. Analysis of variance or Student t-tests were used, and a P < .05 was significant. N = 10 to 12 for all analyses.
Thirty-two patients (12 patients with DVT resolution at 6 months, 10 patients with persistent thrombus at 6 months, and 10 healthy controls) were compared. Both resolving and nonresolving DVT were associated with a 1.5- to 1.8-fold increased vein wall thickness at 6 months (P = .008) as compared with nonaffected vein wall segments. However, the thickness of the affected segments was 1.4-fold greater in patients who had total resolution of the DVT by 6 months than in patients who had persistent chronic thrombus 6 months after presentation (P = .01). There was a four- to five-fold increased level of matrix metalloproteinase-9 (MMP-9) antigen in thrombosed patients compared with nonthrombosed patient controls (P < .05), while Toll-like receptor-9 (TLR-9) gene expression was three-fold less than controls (P < .05) at enrollment. D-dimer and P-selectin were higher in thrombosed as compared to controls at diagnosis but not at 6 months. Both TLR-4 (marker of inflammation) and P-selectin gene expression were higher in leukocytes from patients with chronic DVT compared with those who resolved at 1 month after diagnosis (P < .05).
This preliminary study suggests ongoing vein wall remodeling after DVT, measurable by ultrasound and associated with certain biomarkers. At 6 months, the vein wall is markedly thickened and directly correlates with resolution. This suggests that the vein wall response is initiated early following thrombus formation and persists even in the presence of total resolution.
深静脉血栓形成(DVT)后发生的纤维静脉损伤为血栓后综合征的特征。我们旨在定量评估血栓未能在 6 个月内溶解的患者静脉壁厚度的变化,以及与静脉重塑相关的血液或血浆中炎症蛋白水平是否存在差异。
前瞻性招募患有确诊的下肢 DVT 的患者参与本研究。对下肢静脉系统进行超声检查,并在进入研究时以及在 1 个月和 6 个月时进行超声检查和血液采集时采集血液。通过超声检查定量测量每个受血栓影响的节段的 DVT 溶解和静脉壁厚度,并将对侧不受影响的静脉壁作为对照。分别从白细胞和血清中检测炎症标志物的基因和蛋白表达。使用方差分析或学生 t 检验进行分析,P<.05 为差异有统计学意义。所有分析的 N 值为 10 至 12。
比较了 32 名患者(6 个月时 DVT 溶解的 12 名患者、6 个月时持续性血栓的 10 名患者和 10 名健康对照者)。无论是 DVT 溶解还是不溶解,与未受影响的静脉壁节段相比,6 个月时静脉壁厚度均增加 1.5 至 1.8 倍(P=0.008)。然而,在 6 个月时 DVT 完全溶解的患者中,受累段的厚度比在就诊后 6 个月仍有持续性慢性血栓的患者中增加了 1.4 倍(P=0.01)。与未发生血栓的患者相比,发生血栓的患者基质金属蛋白酶-9(MMP-9)抗原水平增加了 4 至 5 倍(P<.05),而 Toll 样受体-9(TLR-9)基因表达在入院时则减少了 3 倍(P<.05)。与对照组相比,在诊断时 D-二聚体和 P-选择素在发生血栓的患者中更高,但在 6 个月时则不然。与 1 个月时溶解的患者相比,慢性 DVT 患者的白细胞中 TLR-4(炎症标志物)和 P-选择素基因表达更高(P<.05)。
本初步研究表明 DVT 后持续存在静脉壁重塑,可通过超声检测到,并与某些生物标志物相关。在 6 个月时,静脉壁明显增厚,与溶解直接相关。这表明,静脉壁反应在血栓形成后早期即开始,并在完全溶解的情况下仍然存在。